Sterile Injectable Drug Market
Sterile Injectable Drug Market Study by Monoclonal Antibodies, Cytokines, Insulin, Peptide Hormones, Blood Factors, Vaccines, Immunoglobulins, and Peptide Antibiotics from 2024 to 2034
Analysis of Sterile Injectable Drug Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Sterile Injectable Drug Market Outlook (2024 to 2034)
The global sterile injectable drug market size is set to reach a valuation of US$ 611.7 billion in 2024. Sterile injectable drugs are an essential part of the worldwide healthcare sector as they are used for treating life-threatening diseases, including cancer and diabetes, cardiovascular, musculoskeletal, and CNS disorders. Due to the rising importance of sterile injectable drugs in healthcare, the market is projected to increase to a size of US$ 1,277.1 billion by the end of 2034, expanding at 7.6% CAGR.
Sterile injectable drugs are injected directly into the bloodstream or body tissues. Sterile injectables work on the body's inherent defenses, unlike non-sterile medications such as tablets, gels, or aerosols. This delivery method is effective, but it also raises the potential for product contamination for the patient. Sterile injectables must be devoid of bacteria, particles, and other impurities that might endanger a patient. Protecting such sterility necessitates a very specialized manufacturing procedure that is significantly more technically complicated than most other medical items.
Key Market Growth Drivers
- Increasing prevalence of chronic diseases such as diabetes, cancer, or cardiovascular disorders is boosting the need for impactful treatments.
- Demand for small molecule sterile injectable medications is growing because they provide focused therapy, making them ideal for controlling these ailments and tackling the expanding healthcare issues associated with chronic illnesses.
- Biotechnology advancements are promoting the development of innovative sterile injectable drugs, improving efficacy, safety, and targeted delivery.
- These innovations broaden treatment choices, driving sterile injectable drug market growth by providing more effective and accurate pharmaceutical solutions to satisfy a wide range of therapeutic demands.
- Preference for convenience, early initiation of treatment, and greater patient compliance are driving the need for sterile injectable drugs, particularly in conditions that require regular treatment.
- One of the key sterile injectable drug market trends driving sales is the use of self-injectable drugs. Many patients are now looking for home-based treatment, which is fueling the demand for these sterile injectable drugs.
| Report Attributes | Details |
|---|---|
| Sterile Injectable Drug Market Size (2024E) | US$ 611.7 Billion |
| Forecasted Market Value (2034F) | US$ 1,277.1 Billion |
| Global Market Growth Rate (2024 to 2034) | 7.6% CAGR |
| North America Market Share (2024E) | 34.9% |
| East Asia Market Value (2034F) | US$ 240 Billion |
| Sales of Monoclonal Antibodies (2034F) | US$ 277.1 Billion |
| Sales of Large Molecules (2034F) | US$ 674.9 Billion |
| Key Companies Profiled | Pfizer Inc.; Gilead Sciences, Inc.; Baxter International Inc.; Exelixis, Inc.; BioCryst Pharmaceuticals, Inc.; GlaxoSmithKline PLC; Amomed Pharma GmbH; Novartis AG; Sanofi; AstraZeneca; Noxopharm; Gilead Sciences, Inc.; Nova Nordisk A/S; Johnson & Johnson Services, Inc.; Merck & Co., Inc.; Hikma Pharmaceuticals PLC |
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Which Trends in the Pharmaceutical Sector are Driving Sales of Sterile Injectable Drugs?
“Growing Prevalence of Chronic Diseases and Cost-effectiveness of Injectable Drugs”
Demand for sterile injectable drugs is projected to increase over the forecast period as more companies in the pharmaceutical industry are focusing on creating innovative and efficient drugs to treat life-threatening diseases, primarily cancer. Furthermore, the United States FDA's quick approval of sterile injectable pharmaceuticals along with the quicker approval procedures for innovative cancer therapy approaches are expanding drug accessibility and ultimately increasing the need for sterile injectable drugs globally.
- According to a December 2021 study from the International Diabetes Federation, 32.2 billion Americans were estimated to have diabetes in 2021; by 2030, this figure is expected to rise to 57 billion.
Since injectable drugs are often given to senior patients, the need for them is being driven by the rising geriatric population. In addition, the need for injectable pharmaceuticals is projected to rise in the near future owing to demand for affordable pharmaceutical products and the extensive use of generic medications because of their accessibility and affordability.
Patients and medical professionals support the use of generic sterile injectable drugs because they are a more cost-effective therapy option. These factors are contributing to the expansion of the sterile injectable drug market size.
What’s Posing Challenges for Sterile Injectable Drug Producers?
“Excessive Operational Expenses and Availability of Budget-friendly Alternative Options”
Sterile injectable drug manufacturing is complex as it needs proper certification and sterilization for its production. This leads to an increase in operational expenses. Furthermore, the United States FDA's regulations requiring a high standard of care to be followed in the production, packaging, distribution, and storage of sterile injectable pharmaceuticals add to the regulatory burden.
Competition from alternative products, particularly those offering budget-friendly options, often results in the discontinuation of certain injectable drugs, notably in cancer treatment due to their high costs. Rising operational expenses and the discontinuation of sterile injectable drugs pose significant challenges to market expansion.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Country-wise Insights
North America is expected to account for 34.9% market share in 2024 due to the increasing elderly population in the region. The East Asia market is estimated to generate revenue of US$ 90 billion in 2024 due to the vast population and the rising prevalence of chronic diseases.
How Lucrative is the Market for Sterile Injectable Drug Producers in China?
“Strong Manufacturing Base and Rising Elderly Population”
| Attribute | China |
|---|---|
| Market Value (2024E) | US$ 35 Billion |
| Growth Rate (2024 to 2034) | 10.6% CAGR |
| Projected Value (2034F) | US$ 95 Billion |
In East Asia, China is estimated to account for 38.8% sterile injectable drug market share in 2024. Due to the vast population in the country and the rising elderly population, the demand for sterile injectable drugs is increasing. China is also one of the leading players in producing these types of drugs. Owing to a strong manufacturing base, China provides medications at lower rates, which is creating challenges for other countries.
- Tislelizumab, a medication made by BeiGene, was authorized by the China National Medical Products Administration (NMPA) in April 2022 for the treatment of patients with esophageal squamous cell carcinoma (ESCC), a type of esophageal cancer.
Will Increasing Healthcare Investments Drive Market Growth in the United States?
“Growing Focus on Improving Medication for Life-Threatening Diseases”
| Attribute | United States |
|---|---|
| Market Value (2024E) | US$ 184 Billion |
| Growth Rate (2024 to 2034) | 9.6% CAGR |
| Projected Value (2034F) | US$ 461 Billion |
The United States holds a leading market share in the North American region, and the market is estimated to expand 2.5X of its current value in the next 10 years. The country is known for its well-established healthcare sector, and the growing focus on improving treatments for life-threatening diseases such as cancer is leading to heavy investments in research and development. Also, the number of patients with chronic diseases is increasing in the United States, which driving the demand for sterile injectable medicines.
- In August 2021, the Italian company CHEMI SpA and Cadila Healthcare collaborated to introduce the former's generic medications to the United States market.
Category-wise Insights
Why is Demand for Small Molecule Sterile Injectable Drugs Increasing?
“Cost-Effectiveness of Small Molecule Sterile Injectable Drugs”
| Attribute | Small Molecules |
|---|---|
| Segment Value (2024E) | US$ 287.2 Billion |
| Growth Rate (2024 to 2034) | 7.7% CAGR |
| Projected Value (2034F) | US$ 602.2 Billion |
To transfer medicine directly into the bloodstream and ensure prompt and accurate therapeutic effects, small molecule sterile injectable drugs are essential. These medications, which are often used in clinics and hospitals, provide life-saving treatments in emergency and clinical settings while treating a wide range of illnesses, including infections, pain management, and critical care. Also, these are budget-friendly options for patients who want cost-effective treatment. The popularity of small-molecule oncology drugs is also rising with small-molecule sterile injectable drugs.
Why is Application of Sterile Injectable Drugs Growing for Cancer Treatment?
“Minimal Side Effects Associated with Sterile Injectable Drugs”
| Attribute | Cancer |
|---|---|
| Segment Value (2024E) | US$ 106.2 Billion |
| Growth Rate (2024 to 2034) | 7.7% CAGR |
| Projected Value (2034F) | US$ 223.1 Billion |
Rising cancer cases worldwide are significantly contributing to market growth and creating a pressing demand for effective therapeutic solutions such as sterile injectable drugs. Both patients and healthcare professionals are looking for treatments that can also precisely minimize side effects apart from targeting cancer cells. This demand leads to efforts in research and development, resulting in the introduction of new medications and treatments with improved tolerance and efficacy.
- According to World Health Organization (WHO) projections, the number of cancer cases is projected to increase from 18.1 billion in 2018 to 29.4 billion by 2040, indicating an increasing cancer burden.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Competitive Landscape
Key players in the sterile injectable drug market include Pfizer Inc., Gilead Sciences, Inc., Baxter International Inc., Exelixis, Inc., BioCryst Pharmaceuticals, Inc., GlaxoSmithKline plc., Amomed Pharma GmbH, Novartis AG, Sanofi, AstraZeneca, Noxopharm, Gilead Sciences, Inc., Novo Nordisk A/S, and Johnson & Johnson Services, Inc.
- In May 2023, the United States FDA approved the injectable medication Uzedy (risperidone) made by the French company Medincell.
- In November 2022, the FDA approved tremelimumab (Imjudo, AstraZeneca Pharmaceuticals) in combination with durvalumab (Imfinzi, AstraZeneca Pharmaceuticals) and platinum-based chemotherapy for adult patients with metastatic non-small cell lung cancer (NSCLC) lacking sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumor aberrations.
- In May 2022, the FDA approved Mounjaro (tirzepatide) injection, a new once-weekly GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist, manufactured by Eli Lilly and Company. It is recommended as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. Notably, Mounjaro has not been studied in patients with a history of pancreatitis, and it is not recommended for those with type 1 diabetes.
- In October 2020, the European Medicines Agency (EMA) approved the marketing of two new injectable medications, Vocabria injection (cabotegravir) and Rekambys (rilpivirine).
Segmentation of Sterile Injectable Drug Market Research
-
By Type :
- Monoclonal Antibodies
- Cytokines
- Insulin
- Peptide Hormones
- Blood Factors
- Vaccines
- Immunoglobulins
- Peptide Antibiotics
-
By Molecule Type :
- Small Molecules
- Large Molecules
-
By Application :
- Cancer
- Diabetes
- Cardiovascular Diseases
- Musculoskeletal
- CNS
- Infections
-
By Route of Administration :
- Intravenous
- Intramuscular
- Subcutaneous
-
By Distribution Channel :
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
-
By Region :
- North America
- Europe
- Latin America
- East Asia
- South Asia & Oceania
- Middle East & Africa
Table of Content
- 1. Executive Summary
- 2. Market Overview
- 3. Key Market Trends
- 4. Market Background
- 5. Market Context
- 6. Global Market - Pricing Analysis
- 7. Global Market Value Analysis 2018 to 2023 and Forecast, 2024 to 2034
- 8. Global Market Analysis 2018 to 2023 and Forecast 2024 to 2034, By Type
- 8.1. Monoclonal Antibodies
- 8.2. Cytokines
- 8.3. Insulin
- 8.4. Peptide Hormones
- 8.5. Blood Factors
- 8.6. Vaccines
- 8.7. Immunoglobulins
- 8.8. Peptide Antibiotics
- 9. Global Market Analysis 2018 to 2023 and Forecast 2024 to 2034, by Molecule Type
- 9.1. Small Molecules
- 9.2. Large Molecules
- 10. Global Market Analysis 2018 to 2023 and Forecast 2024 to 2034, by Application
- 10.1. Cancer
- 10.2. Diabetes
- 10.3. Cardiovascular Diseases
- 10.4. Musculoskeletal
- 10.5. CNS
- 10.6. Infections
- 11. Global Market Analysis 2018 to 2023 and Forecast 2024 to 2034, by Route of Administration
- 11.1. Intravenous
- 11.2. Intramuscular
- 11.3. Subcutaneous
- 12. Global Market Analysis 2018 to 2023 and Forecast 2024 to 2034, by Distribution Channel
- 12.1. Hospital Pharmacies
- 12.2. Retail Pharmacies
- 12.3. Online Pharmacies
- 13. Global Market Analysis 2018 to 2023 and Forecast 2024 to 2034, by Region
- 13.1. North America
- 13.2. Latin America
- 13.3. Europe
- 13.4. East Asia
- 13.5. South Asia
- 13.6. Oceania
- 13.7. Middle East and Africa (MEA)
- 14. North America Market Analysis 2018 to 2023 and Forecast 2024 to 2034
- 15. Europe Market Analysis 2018 to 2023 and Forecast 2024 to 2034
- 16. Middle East and Africa Market Analysis 2018 to 2023 and Forecast 2024 to 2034
- 17. Rest of the World Market Analysis 2018 to 2023 and Forecast 2024 to 2034
- 18. Key and Emerging Countries Market Analysis 2018 to 2023 and Forecast 2024 to 2034
- 19. Market Structure Analysis
- 20. Competition Analysis
- 20.1. Pfizer Inc.
- 20.2. Gilead Sciences, Inc.
- 20.3. Baxter International Inc.
- 20.4. Exelixis, Inc.
- 20.5. BioCryst Pharmaceuticals, Inc.
- 20.6. GlaxoSmithKline PLC
- 20.7. Amomed Pharma GmbH
- 20.8. Novartis AG
- 20.9. Sanofi
- 20.10. AstraZeneca
- 20.11. Noxopharm
- 20.12. Gilead Sciences, Inc.
- 20.13. Nova Nordisk A/S
- 20.14. Johnson & Johnson Services, Inc.
- 20.15. Merck & Co., Inc.
- 20.16. Hikma Pharmaceuticals PLC
- 21. Assumptions and Acronyms Used
- 22. Research Methodology
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Global Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Type
Table 02: Global Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Molecule Type
Table 03: Global Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Application
Table 04: Global Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Route of Administration
Table 05: Global Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Distribution Channel
Table 06: Global Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Route of Administration Age Group
Table 07: Global Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Region
Table 08: North America Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Country
Table 09: North America Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Type
Table 10: North America Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Application
Table 11: North America Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Molecule Type
Table 12: North America Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Route of Administration
Table 13: North America Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Distribution Channel
Table 14: Europe Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Country
Table 15: Europe Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Type
Table 16: Europe Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Application
Table 17: Europe Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Molecule Type
Table 18: Europe Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Route of Administration
Table 19: Europe Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Distribution Channel
Table 20: Middle East and Africa Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Country
Table 21: Middle East and Africa Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Type
Table 22: Middle East and Africa Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Application
Table 23: Middle East and Africa Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Molecule Type
Table 24: Middle East and Africa Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Route of Administration
Table 25: Middle East and Africa Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Distribution Channel
Table 26: Rest of the World Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Type
Table 27: Rest of the World Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Application
Table 28: Rest of the World Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Molecule Type
Table 29: Rest of the World Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Route of Administration
Table 30: Rest of the World Market Size (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034, By Distribution Channel
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 01: Global Market Value (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034
Figure 02: Global Market Absolute $ Opportunity, 2024 to 2034
Figure 03: Global Market Share Analysis (%), By Type, 2024 & 2034
Figure 04: Global Market Y-o-Y Analysis (%), By Type, 2024 to 2034
Figure 05: Global Market Attractiveness Analysis By Type, 2024 to 2034
Figure 06: Global Market Share Analysis (%), By Molecule Type, 2024 & 2034
Figure 07: Global Market Y-o-Y Analysis (%), By Molecule Type, 2024 to 2034
Figure 08: Global Market Attractiveness Analysis By Molecule Type, 2024 to 2034
Figure 09: Global Market Share Analysis (%), By Application, 2024 & 2034
Figure 10: Global Market Y-o-Y Analysis (%), By Application, 2024 to 2034
Figure 11: Global Market Attractiveness Analysis By Application, 2024 to 2034
Figure 12: Global Market Share Analysis (%), By Route of Administration, 2024 & 2034
Figure 13: Global Market Y-o-Y Analysis (%), By Route of Administration, 2024 to 2034
Figure 14: Global Market Attractiveness Analysis By Route of Administration, 2024 to 2034
Figure 15: Global Market Share Analysis (%), By Distribution Channel, 2024 & 2034
Figure 16: Global Market Y-o-Y Analysis (%), By Distribution Channel , 2024 to 2034
Figure 17: Global Market Attractiveness Analysis, By Distribution Channel, 2024 to 2034
Figure 18: Global Market Share Analysis (%), By Route of Administration Age Group, 2024 & 2034
Figure 19: Global Market Y-o-Y Analysis (%), By Route of Administration Age Group, 2024 to 2034
Figure 20: Global Market Attractiveness Analysis By Route of Administration Age Group, 2024 to 2034
Figure 21: Global Market Share Analysis (%), By Region, 2024 & 2034
Figure 22: Global Market Y-o-Y Analysis (%), By Region, 2024 to 2034
Figure 23: Global Market Attractiveness Analysis, By Region, 2024 to 2034
Figure 24: North America Market Value Share, By Type, 2024 (E)
Figure 25: North America Market Value Share, By Applications 2024 (E)
Figure 26: North America Market Value Share, By Molecule Type, 2024 (E)
Figure 27: North America Market Value Share, By Route of Administration, 2024 (E)
Figure 28: North America Market Value Share, By Distribution Channel, 2024 (E)
Figure 29: North America Market Value Share, By Country, 2024 (E)
Figure 30: North America Market Value (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034
Figure 31: North America Market Attractiveness Analysis By Type, 2024 to 2034
Figure 32: North America Market Attractiveness Analysis By Application, 2024 to 2034
Figure 33: North America Market Attractiveness Analysis By Molecule Type, 2024 to 2034
Figure 34: North America Market Attractiveness Analysis By Route of Administration, 2024 to 2034
Figure 35: North America Market Attractiveness Analysis By Distribution Channel, 2024 to 2034
Figure 36: North America Market Attractiveness Analysis By Country, 2024 to 2034
Figure 37: Europe Market Value Share, By Type, 2024 (E)
Figure 38: Europe Market Value Share, By Applications 2024 (E)
Figure 39: Europe Market Value Share, By Molecule Type, 2024 (E)
Figure 40: Europe Market Value Share, By Route of Administration, 2024 (E)
Figure 41: Europe Market Value Share, By Distribution Channel, 2024 (E)
Figure 42: Europe Market Value Share, By Country, 2024 (E)
Figure 43: Europe Market Value (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034
Figure 44: Europe Market Attractiveness Analysis By Type, 2024 to 2034
Figure 45: Europe Market Attractiveness Analysis By Application, 2024 to 2034
Figure 46: Europe Market Attractiveness Analysis By Molecule Type, 2024 to 2034
Figure 47: Europe Market Attractiveness Analysis By Route of Administration, 2024 to 2034
Figure 48: Europe Market Attractiveness Analysis By Molecule Type, 2024 to 2034
Figure 49: Europe Market Attractiveness Analysis By Country, 2024 to 2034
Figure 50: Middle East and Africa Market Value Share, By Type, 2024 (E)
Figure 51: Middle East and Africa Market Value Share, By Application, 2024 (E)
Figure 52: Middle East and Africa Market Value Share, By Molecule Type, 2024 (E)
Figure 53: Middle East and Africa Market Value Share, By Route of Administration, 2024 (E)
Figure 54: Middle East and Africa Market Value Share, By Distribution Channel, 2024 (E)
Figure 55: Middle East and Africa Market Value Share, By Country, 2024 (E)
Figure 56: Middle East and Africa Market Value (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034
Figure 57: Middle East and Africa Market Attractiveness Analysis By Type, 2024 to 2034
Figure 58: Middle East and Africa Market Attractiveness Analysis By Application, 2024 to 2034
Figure 59: Middle East and Africa Market Attractiveness Analysis By Molecule Type, 2024 to 2034
Figure 60: Middle East and Africa Market Attractiveness Analysis By Route of Administration, 2024 to 2034
Figure 61: Middle East and Africa Market Attractiveness Analysis By Distribution Channel, 2024 to 2034
Figure 62: Middle East and Africa Market Attractiveness Analysis By Country, 2024 to 2034
Figure 63: Rest of the World Market Value Share, By Type, 2024 (E)
Figure 64: Rest of the World Market Value Share, By Applications 2024 (E)
Figure 65: Rest of the World Market Value Share, By Molecule Type, 2024 (E)
Figure 66: Rest of the World Market Value Share, By Route of Administration, 2024 (E)
Figure 67: Rest of the World Market Value Share, By Distribution Channel, 2024 (E)
Figure 68: Rest of the World Market Value (US$ Mn) Analysis 2018 to 2023 and Forecast 2024 to 2034
Figure 69: Rest of the World Market Attractiveness Analysis By Type, 2024 to 2034
Figure 70: Rest of the World Market Attractiveness Analysis By Application, 2024 to 2034
Figure 71: Rest of the World Market Attractiveness Analysis By Molecule Type, 2024 to 2034
Figure 72: Rest of the World Market Attractiveness Analysis By Route of Administration, 2024 to 2034
Figure 73: Rest of the World Market Attractiveness Analysis By Distribution Channel, 2024 to 2034
Figure 74: United States Market Value Share, By Type, 2024 & 2034
Figure 75: United States Market Value Share, By Application, 2024 & 2034
Figure 76: United States Market Value Share, By Molecule Type, 2024 & 2034
Figure 77: United States Market Value Share, By Route of Administration Age Group, 2024 & 2034
Figure 78: United States Market Value Share, By Distribution Channel, 2024 & 2034
Figure 79: United States Market Value Analysis (US$ Mn), 2024 & 2034
Figure 80: Canada Market Value Share, By Type, 2024 & 2034
Figure 81: Canada Market Value Share, By Application, 2024 & 2034
Figure 82: Canada Market Value Share, By Molecule Type, 2024 & 2034
Figure 83: Canada Market Value Share, By Route of Administration Age Group, 2024 & 2034
Figure 84: Canada Market Value Share, By Distribution Channel, 2024 & 2034
Figure 85: Canada Market Value Analysis (US$ Mn), 2024 & 2034
Figure 86: United Kingdom Market Value Share, By Type, 2024 & 2034
Figure 87: United Kingdom Market Value Share, By Application, 2024 & 2034
Figure 88: United Kingdom Market Value Share, By Molecule Type, 2024 & 2034
Figure 89: United Kingdom Market Value Share, By Route of Administration Age Group, 2024 & 2034
Figure 90: United Kingdom Market Value Share, By Distribution Channel, 2024 & 2034
Figure 91: United Kingdom Market Value Analysis (US$ Mn), 2024 & 2034
Figure 92: Germany Market Value Share, By Type, 2024 & 2034
Figure 93: Germany Market Value Share, By Application, 2024 & 2034
Figure 94: Germany Market Value Share, By Molecule Type, 2024 & 2034
Figure 95: Germany Market Value Share, By Route of Administration Age Group, 2024 & 2034
Figure 96: Germany Market Value Share, By Distribution Channel, 2024 & 2034
Figure 97: Germany Market Value Analysis (US$ Mn), 2024 & 2034
Figure 98: France Market Value Share, By Type, 2024 & 2034
Figure 99: France Market Value Share, By Application, 2024 & 2034
Figure 100: France Market Value Share, By Molecule Type, 2024 & 2034
Figure 101: France. Market Value Share, By Route of Administration Age Group, 2024 & 2034
Figure 102: France Market Value Share, By Distribution Channel, 2024 & 2034
Figure 103: France Market Value Analysis (US$ Mn), 2024 & 2034
Figure 104: Italy Market Value Share, By Type, 2024 & 2034
Figure 105: Italy Market Value Share, By Application, 2024 & 2034
Figure 106: Italy Market Value Share, By Molecule Type, 2024 & 2034
Figure 107: Italy Market Value Share, By Route of Administration Age Group, 2024 & 2034
Figure 108: Italy Market Value Share, By Distribution Channel, 2024 & 2034
Figure 109: Italy Market Value Analysis (US$ Mn), 2024 & 2034
Figure 110: Spain Market Value Share, By Type, 2024 & 2034
Figure 111: Spain Market Value Share, By Application, 2024 & 2034
Figure 112: Spain Market Value Share, By Molecule Type, 2024 & 2034
Figure 113: Spain Market Value Share, By Route of Administration Age Group, 2024 & 2034
Figure 114: Spain Market Value Share, By Distribution Channel, 2024 & 2034
Figure 115: Spain Market Value Analysis (US$ Mn), 2024 & 2034
Figure 116: GCC Countries. Market Value Share, By Type, 2024 & 2034
Figure 117: GCC Countries Market Value Share, By Application, 2024 & 2034
Figure 118: GCC Countries Market Value Share, By Molecule Type, 2024 & 2034
Figure 119: GCC Countries Market Value Share, By Route of Administration, 2024 & 2034
Figure 120: GCC Countries Market Value Share, By Distribution Channel, 2024 & 2034
Figure 121: GCC Countries Market Value Analysis (US$ Mn), 2024 & 2034
Figure 122: South Africa Market Value Share, By Type, 2024 & 2034
Figure 123: South Africa Market Value Share, By Application, 2024 & 2034
Figure 124: South Africa Market Value Share, By Molecule Type, 2024 & 2034
Figure 125: South Africa Market Value Share, By Route of Administration Age Group, 2024 & 2034
Figure 126: South Africa Market Value Share, By Distribution Channel, 2024 & 2034
Figure 127: South Africa Market Value Analysis (US$ Mn), 2024 & 2034
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
What is the size of the sterile injectable drug market?
The worldwide market for sterile injectable drugs is estimated at US$ 611.7 billion in 2024.
How big is the sterile injectable drug industry projected to be by 2034?
The global sterile injectable drug market is forecasted to reach US$ 1,277.1 billion by 2034-end.
How fast is the market for sterile injectable drugs expanding?
The market is projected to expand at a CAGR of 7.6% between 2024 to 2034.
What are the top sterile injectable drug companies?
Key market players are Pfizer Inc., Gilead Sciences, Inc., Baxter International Inc., and Exelixis, Inc.
At what pace is the market expected to grow in Japan?
The market in Japan is projected to expand at a CAGR of 10% through 2034.
What are the projected sales of insulin for 2034?
Insulin sales are projected to register 8% CAGR and reach US$ 167.2 billion by 2034.
What is the estimated revenue from large molecule sterile injectable drugs?
The market for large molecule sterile injectable drugs is estimated to reach US$ 674.9 billion by 2034.
Sterile Injectable Drug Market